Medical Management of COVID-19: Evidence and Experience

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2020 Jun 27

PMID 32587649

Citations 22

Authors

Subhasish Bose

Sreedhar Adapa

Narothama Reddy Aeddula

Sasmit Roy

Deepak Nandikanti

Phani Mohan Vupadhyayula

Srikanth Naramala

Vijay Gayam

Vijayadershan Muppidi

Venu Madhav Konala

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale, as of June 1, 2020, the World Health Organization (WHO) published statistics of 6,057,853 infected patients and 371,166 deaths worldwide. Despite reported observational data about the experimental use of certain drugs, there is no conclusively proven curative therapy for COVID-19 as of now; however, remdesivir received emergency use authorization (EUA) by the Food and Drug Administration (FDA) recently for use in patients hospitalized with COVID-19. There are several ongoing clinical trials related to the pharmacological choices of therapy for COVID-19 patients; however, drug trials related to observational studies so far have yielded mixed results and therefore have created a sense of confusion among healthcare professionals (HCPs). In this review article, we seek to collate and provide a summary of treatment strategies for COVID-19 patients with a variable degree of illness and discuss pharmacologic and other therapies intended to be used either as experimental medicine/therapy or as part of supportive care in complicated cases of COVID-19.

Citing Articles

Clinical Comparison of COVID Waves 2-5. An Inpatient Retrospective Comparative Analysis From Karachi, Pakistan.

Sayeed M, Shalim E, Farman S, Farooqui F, Syed B, Ahmed I Open Forum Infect Dis. 2025; 12(3):ofaf072.

PMID: 40066088 PMC: 11890920. DOI: 10.1093/ofid/ofaf072.

Inpatient Physician and Nurse Experience During the COVID-19 Crisis at a Public Safety Net Hospital.

Nayak S, Waters A, Warsi M, Hegde A, Chu E Brown J Hosp Med. 2025; 2(1):57694.

PMID: 40046543 PMC: 11878838. DOI: 10.56305/001c.57694.

Case-control association study between polygenic risk score and COVID-19 severity in a Russian population using low-pass genome sequencing.

Nostaeva A, Shimansky V, Apalko S, Kuznetsov I, Sushentseva N, Popov O Epidemiol Infect. 2024; 153():e13.

PMID: 39721951 PMC: 11748017. DOI: 10.1017/S0950268824001778.

A Comprehensive Review on Navigating the Neurological Landscape of COVID-19: Insights Into Etiopathogenesis and Clinical Management.

Chavhan R, Wanjari A, Kumar S, Acharya S, Rathod N, Reddy H Cureus. 2024; 16(5):e60079.

PMID: 38860093 PMC: 11163389. DOI: 10.7759/cureus.60079.

Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review.

Kandula U, Wake A Biologics. 2023; 17:85-112.

PMID: 37223116 PMC: 10202141. DOI: 10.2147/BTT.S404421.

References

Chang J . Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J. 2019; 17:10. PMC: 6542012. DOI: 10.1186/s12959-019-0198-4. View

Chen L, Xiong J, Bao L, Shi Y . Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20(4):398-400. PMC: 7128218. DOI: 10.1016/S1473-3099(20)30141-9. View

Pan C, Chen L, Lu C, Zhang W, Xia J, Sklar M . Lung Recruitability in COVID-19-associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study. Am J Respir Crit Care Med. 2020; 201(10):1294-1297. PMC: 7233342. DOI: 10.1164/rccm.202003-0527LE. View

Retallack H, Di Lullo E, Arias C, Knopp K, Laurie M, Sandoval-Espinosa C . Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016; 113(50):14408-14413. PMC: 5167169. DOI: 10.1073/pnas.1618029113. View

Zhang W, Wang J, Su B, Li R, Ding Z, Kang Y . Cimetidine augments Th1/Th2 dual polarized immune responses to recombinant HBV antigens. Vaccine. 2011; 29(29-30):4862-8. DOI: 10.1016/j.vaccine.2011.03.091. View

Monard C, Rimmele T, Ronco C . Extracorporeal Blood Purification Therapies for Sepsis. Blood Purif. 2019; 47 Suppl 3:1-14. DOI: 10.1159/000499520. View

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

10.

Carlos D, Spiller F, Souto F, Trevelin S, Borges V, de Freitas A . Histamine h2 receptor signaling in the pathogenesis of sepsis: studies in a murine diabetes model. J Immunol. 2013; 191(3):1373-82. DOI: 10.4049/jimmunol.1202907. View

11.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

12.

Kurzrock R, Auber M, Mavligit G . Cimetidine therapy of herpes simplex virus infections in immunocompromised patients. Clin Exp Dermatol. 1987; 12(5):326-31. DOI: 10.1111/j.1365-2230.1987.tb02501.x. View

13.

Alhazzani W, Moller M, Arabi Y, Loeb M, Gong M, Fan E . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5):854-887. PMC: 7101866. DOI: 10.1007/s00134-020-06022-5. View

14.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

15.

Hurst M, Faulds D . Lopinavir. Drugs. 2001; 60(6):1371-9; discussion 1380-1. DOI: 10.2165/00003495-200060060-00009. View

16.

Fernandez-Ruiz M, Andres A, Loinaz C, Delgado J, Lopez-Medrano F, San Juan R . COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020; 20(7):1849-1858. PMC: 9800471. DOI: 10.1111/ajt.15929. View

17.

Chan J, Yao Y, Yeung M, Deng W, Bao L, Jia L . Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015; 212(12):1904-13. PMC: 7107395. DOI: 10.1093/infdis/jiv392. View

18.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

19.

Liu Y . IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306. DOI: 10.1146/annurev.immunol.23.021704.115633. View

20.

Luks A, Freer L, Grissom C, McIntosh S, Schoene R, Swenson E . COVID-19 Lung Injury is Not High Altitude Pulmonary Edema. High Alt Med Biol. 2020; 21(2):192-193. DOI: 10.1089/ham.2020.0055. View